- Home
- SELF vs NRXP Comparison
SELF vs NRXP Comparison
Compare SELF & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | NRXP |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SELF | NRXP |
|---|---|---|
| Price | $5.02 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 27.5K | ★ 446.3K |
| Earning Date | 11-07-2025 | 11-17-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | $242,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | $643.59 |
| P/E Ratio | $31.13 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $1.15 |
| 52 Week High | $5.89 | $6.01 |
Technical Indicators
Market Signals| Indicator | SELF | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 45.23 |
| Support Level | $5.03 | $2.22 |
| Resistance Level | $5.17 | $2.51 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 8.70 | 68.52 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.